Presence and impact of antidrug antibodies (adas) to tremelimumab (t) or durvalumab (d) in the phase 3 himalaya study of unresectable hepatocellular carcinoma (uhcc)
| dc.contributor.author | Galle, P. R. | |
| dc.contributor.author | Crysler, O., V | |
| dc.contributor.author | Yarchoan, M. | |
| dc.contributor.author | Furuse, J. | |
| dc.contributor.author | Sukeepaisarnjaroen, W. | |
| dc.contributor.author | Thinh, N. T. | |
| dc.contributor.author | Masi, G. | |
| dc.contributor.author | Lim, H. Y. | |
| dc.contributor.author | Varela Calvo, María | |
| dc.contributor.author | Gupta, C. | |
| dc.contributor.author | Makowsky, M. | |
| dc.contributor.author | Negro, A. | |
| dc.contributor.author | Abou Alfa, G. K. | |
| dc.date.accessioned | 2024-08-26T08:33:00Z | |
| dc.date.available | 2024-08-26T08:33:00Z | |
| dc.date.issued | 2023 | |
| dc.identifier.issn | 2296-5270 | |
| dc.identifier.issn | 2296-5262 | |
| dc.identifier.uri | https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.4_suppl.551 | |
| dc.identifier.uri | https://hdl.handle.net/10651/74129 | |
| dc.format.extent | p. 129-129 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Oncology Research and Treatment | |
| dc.rights | ©, | |
| dc.source | WOS:001091456900277 | |
| dc.title | Presence and impact of antidrug antibodies (adas) to tremelimumab (t) or durvalumab (d) in the phase 3 himalaya study of unresectable hepatocellular carcinoma (uhcc) | |
| dc.type | conference output |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||